دورية أكاديمية
أعرض في EDS

Emerging phenotypes in kidney transplant rejection.

التفاصيل البيبلوغرافية
العنوان: Emerging phenotypes in kidney transplant rejection.
المؤلفون: Mengel M; Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada., Adam BA
المصدر: Current opinion in organ transplantation [Curr Opin Organ Transplant] 2024 Apr 01; Vol. 29 (2), pp. 97-103. Date of Electronic Publication: 2023 Nov 30.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9717388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-7013 (Electronic) Linking ISSN: 10872418 NLM ISO Abbreviation: Curr Opin Organ Transplant Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Rapid Science Publishers,
مواضيع طبية MeSH: Kidney Transplantation*/adverse effects, Humans ; Graft Rejection/diagnosis ; Graft Rejection/prevention & control ; Kidney ; Transplantation, Homologous ; Biopsy ; Postoperative Complications
مستخلص: Purpose of Review: This review focuses on more recently emerging rejection phenotypes in the context of time post transplantation and the resulting differential diagnostic challenges. It also discusses how novel ancillary diagnostic tools can potentially increase the accuracy of biopsy-based rejection diagnosis.
Recent Findings: With advances in reducing immunological risk at transplantation and improved immunosuppression treatment renal allograft survival improved. However, allograft rejection remains a major challenge and represent a frequent course for allograft failure. With prolonged allograft survival, novel phenotypes of rejection are emerging, which can show complex overlap and transition between cellular and antibody-mediated rejection mechanisms as well as mixtures of acute/active and chronic diseases. With the emerging complexity in rejection phenotypes, it is crucial to achieve diagnostic accuracy in the individual patient.
Summary: The prospective validation and adoption of novel molecular and computational diagnostic tools into well defined and appropriate clinical context of uses will improve our ability to accurately diagnose, stage, and grade allograft rejection.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388–399.
Loupy A, Mengel M, Haas M. Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics. Kidney international 2022; 101:678–691.
Short S, Lewik G, Issa F. An immune atlas of T cells in transplant rejection: pathways and therapeutic opportunities. Transplantation 2023; 107:2341–2352.
Nickeleit V, Mengel M, Colvin RB. Heptinstall's pathology of the kidney, 7th ed. Chapter 29. Renal transplant pathology. 2014.
Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation 2018; 102:1795–1814.
Ho J, Okoli GN, Rabbani R, et al. Effectiveness of T cell-mediated rejection therapy: a systematic review and meta-analysis. Am J Transplant 2022; 22:772–785.
Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7:356–365.
Mengel M, Reeve J, Bunnag S, et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9:1859–1867.
Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10:2066–2073.
Gago M, Cornell LD, Kremers WK, et al. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012; 12:1199–1207.
Naesens M, Kuypers DR, De Vusser K, et al. Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013; 13:86–99.
Lefaucheur C, Gosset C, Rabant M, et al. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant 2018; 18:377–390.
Nankivell BJ, Shingde M, Keung KL, et al. The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: the Banff i-IFTA lesion. Am J Transplant 2018; 18:364–376.
Sellarés J, de Freitas DG, Mengel M, et al. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 2011; 11:489–499.
Famulski KS, Reeve J, de Freitas DG, et al. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant 2013; 13:634–644.
Adam BA, Kikic Z, Wagner S, et al. Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: prospects for molecular diagnosis and risk prediction. Am J Transplant 2020; 20:3486–3501.
Adam BA, Murakami N, Reid G, et al. Gene expression profiling in kidney transplants with immune checkpoint inhibitor-associated adverse events. Clin J Am Soc Nephrol 2021; 16:1376–1386.
Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant 2010; 10:1126–1134.
Einecke G, Melk A, Ramassar V, et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005; 5:1827–1836.
Einecke G, Fairhead T, Hidalgo LG, et al. Tubulitis and epithelial cell alterations in mouse kidney transplant rejection are independent of CD103, perforin or granzymes A/B. Am J Transplant 2006; 6:2109–2120.
Rampersad C, Balshaw R, Gibson IW, et al. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant 2022; 22:761–771.
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 2018; 18:293–307.
Matas AJ, Helgeson ES, Gaston R, et al. Inflammation in areas of fibrosis: the DeKAF prospective cohort. Am J Transplant 2020; 20:2509–2521.
Nakagawa K, Tsuchimoto A, Ueki K, et al. Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant 2021; 21:174–185.
Helgeson ES, Mannon R, Grande J, et al. i-IFTA and chronic active T cell-mediated rejection: a tale of 2 (DeKAF) cohorts. Am J Transplant 2021; 21:1866–1877.
Naesens M, Roufosse C, Haas M, et al. The Banff 2022 Kidney Meeting Report: re-appraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant 2023; [Online ahead of print].
Fitzsimmons WE, Naesens M. Acute rejection after kidney transplant: an endpoint not predictive of treatment effect on graft survival. Transplantation 2023; doi: 10.1097/TP.0000000000004696. [Online ahead of print]. (PMID: 10.1097/TP.0000000000004696.)
Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med 2018; 379:1150–1160.
Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708–714.
Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272–283.
Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10:2215–2222.
Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 2020; 20:2318–2331.
Callemeyn J, Ameye H, Lerut E, et al. Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. Am J Transplant 2021; 21:2413–2423.
Schinstock CA, Sapir-Pichhadze R, Naesens M, et al. Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: diagnostic misinterpretation has potential therapeutic implications. Am J Transplant 2019; 19:123–131.
Mengel M, Mannon RB. Banff and ABMR: are we going in the right direction? Am J Transplant 2021; 21:2321–2322.
Schinstock CA, Mannon RB, Budde K, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation 2020; 104:911–922.
Haas M, Mirocha J, Huang E, et al. A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection. Kidney Int 2023; 103:187–195.
Senev A, Callemeyn J, Lerut E, et al. Histological picture of ABMR without HLA-DSA: temporal dynamics of effector mechanisms are relevant in disease reclassification. Am J Transplant 2019; 19:954–955.
Buxeda A, Llinàs-Mallol L, Gimeno J, et al. Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d: an orphan category in Banff classification with cytotoxic T and natural killer cell infiltration. Am J Transplant 2023; 23:464–474.
Coemans M, Senev A, Van Loon E, et al. The evolution of histological changes suggestive of antibody-mediated injury, in the presence and absence of donor-specific anti-HLA antibodies. Transplant Int 2021; 34:1824–1836.
Callemeyn J, Lerut E, de Loor H, et al. Transcriptional changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies. J Am Soc Nephrol 2020; 31:2168–2183.
Halloran PF, Madill-Thomsen KS, Pon S, et al. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes. Am J Transplant 2022; 22:1976–1991.
Senev A, Van Loon E, Lerut E, et al. Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies. Kidney Int 2021; 100:401–414.
Koenig A, Chen CC, Marçais A, et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nat Commun 2019; 10:5350.
Koenig A, Mezaache S, Callemeyn J, et al. Missing self-induced activation of NK cells combines with non-complement-fixing donor-specific antibodies to accelerate kidney transplant loss in chronic antibody-mediated rejection. J Am Soc Nephrol 2021; 32:479–494.
Callemeyn J, Senev A, Coemans M, et al. Missing self-induced microvascular rejection of kidney allografts: a population-based study. J Am Soc Nephrol 2021; 32:2070–2082.
Mengel M, Loupy A, Haas M, et al. Banff 2019 Meeting Report: molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 2020; 20:2305–2317.
Beadle J, Papadaki A, Toulza F, et al. Application of the Banff Human Organ Transplant Panel to kidney transplant biopsies with features suspicious for antibody-mediated rejection. Kidney Int 2023; 104:526–541.
Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157–1167.
Davis S, Wiebe C, Campbell K, et al. Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. Am J Transplant 2021; 21:322–328.
Wiebe C, Rush DN, Gibson IW, et al. Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection. Am J Transplant 2020; 20:2499–2508.
Wiebe C, Nickerson PW. Human leukocyte antigen molecular mismatch to risk stratify kidney transplant recipients. Curr Opin Organ Transplant 2020; 25:8–14.
Wiebe C, Nickerson P. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013; 18:470–477.
Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. Am J Transplant 2018; 18:785–795.
Callemeyn J, Lamarthée B, Koenig A, et al. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int 2022; 101:692–710.
Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (London, England) 2013; 381:313–319.
Rosales IA, Smith RN, Colvin RB. Histologic and molecular features of antibody-mediated rejection. Curr Opin Organ Transplant 2023; 28:340–344.
Rosales IA, Mahowald GK, Tomaszewski K, et al. Banff human organ transplant transcripts correlate with renal allograft pathology and outcome: importance of capillaritis and subpathologic rejection. J Am Soc Nephrol 2022; 33:2306–2319.
Lamarthée B, Callemeyn J, Van Herck Y, et al. Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat Commun 2023; 14:4359.
McDaniels JM, Shetty AC, Kuscu C, et al. Single nuclei transcriptomics delineates complex immune and kidney cell interactions contributing to kidney allograft fibrosis. Kidney Int 2023; 103:1077–1092.
Vaulet T, Divard G, Thaunat O, et al. Data-driven chronic allograft phenotypes: a novel and validated complement for histologic assessment of kidney transplant biopsies. J Am Soc Nephrol 2022; 33:2026–2039.
Labriffe M, Woillard JB, Gwinner W, et al. Machine learning-supported interpretation of kidney graft elementary lesions in combination with clinical data. Am J Transplant 2022; 22:2821–2833.
Aubert O, Higgins S, Bouatou Y, et al. Archetype analysis identifies distinct profiles in renal transplant recipients with transplant glomerulopathy associated with allograft survival. J Am Soc Nephrol 2019; 30:625–639.
Halloran PF, Madill-Thomsen KS, Reeve J. The molecular phenotype of kidney transplants: insights from the MMDx project. Transplantation 2023; doi: 10.1097/TP.0000000000004624. [Online ahead of print]. (PMID: 10.1097/TP.0000000000004624.)
Loupy A, Aubert O, Orandi BJ, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ (Clinical research ed) 2019; 366:l4923.
Yoo D, Goutaudier V, Divard G, et al. An automated histological classification system for precision diagnostics of kidney allografts. Nat Med 2023; 29:1211–1220.
Roufosse C, Naesens M, Haas M, et al. The Banff 2022 Kidney Meeting Work Plan: data-driven refinement of the Banff classification for renal allografts. Am J Transplant 2023; S1600-6135(23)00855-9. doi: 10.1016/j.ajt.2023.10.031. [Online ahead of print]. (PMID: 10.1016/j.ajt.2023.10.031.)
Solez K, Colvin RB, Racusen LC, et al. Banff ’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (’CAN’). Am J Transplant 2007; 7:518–526.
تواريخ الأحداث: Date Created: 20231130 Date Completed: 20240308 Latest Revision: 20240604
رمز التحديث: 20240604
DOI: 10.1097/MOT.0000000000001130
PMID: 38032262
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-7013
DOI:10.1097/MOT.0000000000001130